Sirnaomics Initiates Phase 2b Study using STP705 for treatment of Squamous Cell Skin Cancer

Surgery is currently the most common treatment option for the treatment of NMSC which often carry significant cutaneous adverse events, risk of scar, infection, bleeding and recurrence

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced the initiation of the Phase 2b study of the company's lead drug candidate, STP705, for the treatment of squamous cell skin cancer.

The randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of intralesional injection of STP705 in 100 adult patients with squamous cell carcinoma in situ (isSCC). This is a two-part dose-escalation trial; in the run-in period, the 30 ug and 60 ug dosing regimens from the Phase 2a study of STP705 will be further evaluated, in addition to a third new dose level. The second part of the trial will further evaluate the two most efficacious dosing regimens. The primary endpoint of this trial is the proportion of participants with histological clearance of treated isSCC lesions at the end of treatment. Histological clearance will be defined as the absence of detectable evidence of isSCC tumor cell nests as determined by central pathology review.

"In the recently concluded Phase 2a clinical trial of STP705 in isSCC, a high rate of patients achieved histological clearance in a dose dependent manner, which is the gold standard for skin cancer," said Patrick Lu, Ph.D., the founder, President and CEO of Sirnaomics. "As we initiate the Phase 2b trial, we are hopeful to learn more about the potential of this non-surgical, non-invasive treatment for common non-melanoma skin cancer, and more broadly the promise of RNAi therapeutics in oncology."

"isSCC continues to be a disease with high unmet therapeutic need where surgery is still considered the only viable treatment option for many patients," said Michael Molyneaux M.D., Chief Medical Officer of Sirnaomics. "We hope to build on the success we have seen in the Phase 2a study, where we achieved 90% histological clearance rates in the 30 ug and 60 ug dosing groups. We anticipate having an interim data readout late second half of 2021 that will guide our clinical development for this indication."

About Non-melanoma Skin Cancer and Squamous Cell Carcinoma In Situ
Skin cancer is the most common type of all cancers diagnosed each year in the United States. It is estimated that nearly half of cancers diagnosed every year will be skin cancers. Over the past decade, the incidence of skin cancers has increased dramatically. According to the JAMA Dermatology paper (Rogers, et. al. JAMA Dermatol. 2015151(10):1081-1086), an estimated 3.3 million people in the US suffer from non-melanoma skin cancer (NMSC) along with 5.43 million people that are currently living with cancer lesions. Data on specific types of NMSC were 2.55 million cases for basal cell carcinoma (47%): 2.57 million cases for squamous cell carcinoma including squamous cell carcinoma in situ (46.7%), plus another 332,000 cases of unspecified type of skin cancers.

A World Health Organization authorized report from "International Agency for Research on Cancer" (2019) has demonstrated that the number of deaths in 2018 globally for both men and women from NMSC is 65,155, where the mortality of Asia NMSC patients represents 41.9% of the global total, significantly more than other individual areas.

Squamous cell carcinoma in situ, also called Bowen disease, is the earliest form of squamous cell skin cancer (SCC). Along with basal cell carcinoma, SCC is one of two major subtypes of NMSC. The key driver for development of SCC is ultraviolet rays from the sun. It is believed that development of SCC is linked closely to genomic perturbations, genetic mutations, and altered expression of key molecules (e.g., overexpression of TGF-β1 and COX-2) that impacts squamous cell lineage commitment and terminal differentiation.

Surgery is currently the most common treatment option for the treatment of NMSC. The various forms of surgical modalities carry significant cutaneous adverse events, risk of scar, infection, and bleeding. Surgery can also have a significant recurrence rate. As a result, there is a high unmet need for an FDA approved local injection therapy that is safe and effective.

About STP705
Sirnaomics' leading product candidate, STP705, is a siRNA (small interfering RNA) therapeutic that takes advantage of a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to directly knock down both TGF-β1 and COX-2 gene expression. The product candidate has received multiple IND approvals from both the US FDA and Chinese NMPA, including treatments of cholangiocarcinoma, nonmelanoma skin cancer and hypertrophic scar. STP705 has also received Orphan Drug Designation for treatment of cholangiocarcinoma and primary sclerosing cholangitis. STP705 is currently in four clinical trials for different indications. A Phase 2a study of STP705 for treatment of squamous cell skin cancer (isSCC) in adult patients demonstrated positive efficacy and safety results, with 76% of all patients (19/25) achieving complete histologically clearance and the two optimal dosing ranges achieving 90% histological clearance of tumor cell in the lesion. No significant or serious adverse events, including no significant cutaneous skin reactions, were reported in the study, and the company was able to define a clear therapeutic window in advance of later stage studies.

Tags : #Siranomics #SquamousCellSkinCancer #NMSC #SkinCancer #SkinCancerTreatment #FDA

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Are we delivering new HIV prevention tools with speed, scale and equity?October 14, 2024
Hospital Lab Management: City Imaging & Clinical Labs to Expand Services to 50 Hospitals in North India by March 2027October 14, 2024
Women at Risk: India’s Breast Cancer Crisis and Its Impact on Future GenerationsOctober 14, 2024
Genetics or Lifestyle: Who’s Really to Blame for Your Premature Hair Loss?October 14, 2024
Decoding Parenthood: How Carrier Screening Can Shape a Healthier Future for India’s FamiliesOctober 14, 2024
Katrina Kaif Presents Kay Beauty’s Velvet Crème Blush: An iconic collectible multi-Use Magic blush in a revolutionary cushion crème-to-powder formulaOctober 11, 2024
Aakash Healthcare goes a step ahead: Movie Shows and Weekend Family Drives for doctors and nurses – Where work-life balance meets fun!October 11, 2024
Not Just a Day, But a Movement: The Real Impact of International Girl Child Day in IndiaOctober 11, 2024
From Darkness to Light: How India Wiped Out a Leading Cause of BlindnessOctober 11, 2024
India’s Diet Could Save the Planet: Why the World Needs to Follow Its Lead by 2050October 11, 2024
Is Your Brain Cleansing Itself? Discover the System That Could Save Your MindOctober 10, 2024
The Dark Side of Desire: How Personality Traits Influence Sexual BehaviorsOctober 10, 2024
India’s Mental Health Time Bomb: Can We Afford to Ignore It Any Longer?October 10, 2024
Go Cheese Announces Strategic Collaboration with Bigg Boss Season 18 to Enhance Brand Engagement and Consumer Reach Across IndiaOctober 10, 2024
DKMS BMST Foundation India Expands Stem Cell Donor Registry with 400+ New Donors registered from IIT DelhiOctober 10, 2024
FLAME University Launches the Centre for Research in Wellbeing and Happiness on International Day of Older PersonsOctober 10, 2024
Kaya Expands in Ludhiana with its 76th Clinic, Elevating Skincare with Advanced Wellness Solutions October 09, 2024
Dr Raj Nagarkar Becomes India’s 1st Oncologist on Cambridge Medical Robotics’ Advisory BoardOctober 09, 2024
Workplace Stress and Burnout Rate Reaching Critical Levels for Indian Employees, Warn ExpertsOctober 09, 2024
Are We Really Living Longer? The Surprising Reality of Life Expectancy TodayOctober 09, 2024